Arid
DOI10.1016/j.nucmedbio.2010.11.001
Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging
Zha, Zhihao1,2; Zhu, Lin1,2; Liu, Yajing2; Du, Fenghua2; Gan, Hongmei2; Qiao, Jinping2; Kung, Hank F.1,2
通讯作者Kung, Hank F.
来源期刊NUCLEAR MEDICINE AND BIOLOGY
ISSN0969-8051
出版年2011
卷号38期号:4页码:501-508
英文摘要

Introduction: Nitroimidazole (azomycin) derivatives labeled with radioisotopes have been developed as cancer imaging and radiotherapeutic agents based on the oncological hypoxic mechanism. By attaching nitroimidazole core with different functional groups, we synthesized new nitroimidazole derivatives and evaluated their potentiality as tumor imaging agents.


Methods: Starting with commercially available 2-nitroimidazole, 2-fluoro-N-(2-(2-nitro-1H-imidazol-1-yl)ethyl)acetamide (NEFA, [(19)F]7) and 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 2-fluoroacetate (NEFT, [(19)F]8), as well as radiolabeling precursors, the bromo-substituted analogs were quickly synthesized through a three-step synthetic pathway. The precursors were radiolabeled with [(18)F]F(-)/18-crown-6/KHCO(3) in dimethyl sulfoxide at 90 degrees C for 10 min followed by purification with an Oasis HLB cartridge. Biodistribution studies were carried out in EMT-6 tumor-bearing mice. The uptake (%ID/g) in tumors and normal tissues were measured at 30 min postinjection. Liquid chromatography-electrospray ionization mass spectrometry (LC/MS) was used to distinguish metabolites from parent drugs in urine and plasma of rat injected with "cold" NEFA ([(19)F]7) and NEFT ([(19)F]8).


Results: Two radiotracers, [(18)F]NEFA ([(18)F]7) and [(18)F]NEFT ([(18)F]8), were prepared with average yields of 6%-7% and 9%-10% (not decay corrected). Radiochemical purity for both tracers was >95% as determined by HPLC. Biodistribution studies in EMT-6 tumor-bearing mice indicated that the tumor to blood and tumor to liver ratios of both [(18)F]7 (0.96, 0.61) and [(18)F]8 (0.98, 1.10) at 30 min were higher than those observed for [(18)F]FMISO (1) (0.91, 0.59), a well-investigated azomycin-type hypoxia radiotracer. Liquid chromatography-electrospray ionization mass spectrometry analysis demonstrated that fluoroacetate was the main in vivo metabolite for both NEFA ([(19)F]7) and NEFT ([(19)F]8).


Conclusions: In this research, two new fluorine-18 labeled 2-nitroimidazole derivatives, [(18)F]7 and [(18)F]8, both of which containing in vivo hydrolyzable group, were successfully prepared. Further biological evaluations are warranted to investigate their potential as PET radioligands for imaging tumor. (C) 2011 Elsevier Inc. All rights reserved.


英文关键词PET 2-Nitroimidazole (18)F hypoxia
类型Article
语种英语
国家USA ; Peoples R China
收录类别SCI-E
WOS记录号WOS:000290601300007
WOS关键词IN-VIVO EVALUATION ; HYPOXIC CELLS ; RADIOLABELED FLUOROMISONIDAZOLE ; MARKER ; AGENT
WOS类目Radiology, Nuclear Medicine & Medical Imaging
WOS研究方向Radiology, Nuclear Medicine & Medical Imaging
来源机构北京师范大学
资源类型期刊论文
条目标识符http://119.78.100.177/qdio/handle/2XILL650/169804
作者单位1.Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA;
2.Beijing Normal Univ, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
推荐引用方式
GB/T 7714
Zha, Zhihao,Zhu, Lin,Liu, Yajing,et al. Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging[J]. 北京师范大学,2011,38(4):501-508.
APA Zha, Zhihao.,Zhu, Lin.,Liu, Yajing.,Du, Fenghua.,Gan, Hongmei.,...&Kung, Hank F..(2011).Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging.NUCLEAR MEDICINE AND BIOLOGY,38(4),501-508.
MLA Zha, Zhihao,et al."Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging".NUCLEAR MEDICINE AND BIOLOGY 38.4(2011):501-508.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zha, Zhihao]的文章
[Zhu, Lin]的文章
[Liu, Yajing]的文章
百度学术
百度学术中相似的文章
[Zha, Zhihao]的文章
[Zhu, Lin]的文章
[Liu, Yajing]的文章
必应学术
必应学术中相似的文章
[Zha, Zhihao]的文章
[Zhu, Lin]的文章
[Liu, Yajing]的文章
相关权益政策
暂无数据
收藏/分享

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。